Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1957 2
1963 1
1967 1
1973 1
1974 1
1978 1
1979 2
1981 1
1982 1
1983 1
1985 1
1988 1
1991 1
1992 1
1993 2
1994 3
1995 2
1996 5
1997 3
1998 2
1999 3
2000 7
2001 10
2002 8
2003 11
2004 10
2005 14
2006 23
2007 29
2008 24
2009 21
2010 30
2011 21
2012 30
2013 40
2014 43
2015 32
2016 39
2017 33
2018 34
2019 39
2020 47
2021 59
2022 60
2023 62
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

681 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. Among authors: chu cy. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H; JADE COMPARE Investigators. Bieber T, et al. Among authors: chu cy. N Engl J Med. 2021 Mar 25;384(12):1101-1112. doi: 10.1056/NEJMoa2019380. N Engl J Med. 2021. PMID: 33761207 Clinical Trial.
Ligelizumab for Chronic Spontaneous Urticaria.
Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, Bernstein JA, Brehler R, Chu CY, Chung WH, Danilycheva I, Grattan C, Hébert J, Katelaris C, Makris M, Meshkova R, Savic S, Sinclair R, Sitz K, Staubach P, Wedi B, Löffler J, Barve A, Kobayashi K, Hua E, Severin T, Janocha R. Maurer M, et al. Among authors: chu cy. N Engl J Med. 2019 Oct 3;381(14):1321-1332. doi: 10.1056/NEJMoa1900408. N Engl J Med. 2019. PMID: 31577874 Free article. Clinical Trial.
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaçi D, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. Guttman-Yassky E, et al. Among authors: chu cy. Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21. Lancet. 2021. PMID: 34023008 Clinical Trial.
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, Calimlim BM, Thyssen JP, Chiou AS, Bissonnette R, Stein Gold LF, Wegzyn C, Hu X, Liu M, Liu J, Tenorio AR, Chu AD, Guttman-Yassky E. Simpson EL, et al. Among authors: chu cy. JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029. JAMA Dermatol. 2022. PMID: 35262646 Free PMC article.
Annular drug eruptions.
Wu WH, Chu CY. Wu WH, et al. Among authors: chu cy. Clin Dermatol. 2022 Sep-Oct;40(5):450-465. doi: 10.1016/j.clindermatol.2021.12.008. Epub 2021 Dec 31. Clin Dermatol. 2022. PMID: 34979270
Urticaria and the gut.
Chu CY, Zuberbier T. Chu CY, et al. Curr Opin Allergy Clin Immunol. 2020 Aug;20(4):381-385. doi: 10.1097/ACI.0000000000000653. Curr Opin Allergy Clin Immunol. 2020. PMID: 32590507 Review.
Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus.
Brüggen MC, Walsh S, Ameri MM, Anasiewicz N, Maverakis E, French LE, Ingen-Housz-Oro S; DRESS Delphi consensus group; Abe R, Ardern-Jones M, Assier H, Barbaud A, Bensaid B, Bernal W, Bernier C, Brassard A, Brezinová E, Cabañas R, Cardones A, Chu CY, Chua SL, Descamps V, Didona B, Divito SJ, Dodiuk-Gad R, Elman S, Gaspar K, Mortz CG, Hama N, Lee HY, Horváth B, Jörg L, Kaffenberger BH, Kucinskiene V, Lebrun-Vignes B, Lehloenya RJ, Meyersburg D, Micheletti R, Milpied B, Miyagawa F, Mostaghimi A, Nägeli M, Naldi L, Oppel E, Phillips EJ, Pirani T, Ranki A, Mälkönen T, Rosenbach M, Salavastru C, Staumont-Salle D, Sandberg H, Setterfield J, Shinkai K, Shiohara T, Soria A, Tartar D, Tiplica GS, Traidl S, Vorobyev A, von Wachter C, Worswick S, Cho YT. Brüggen MC, et al. Among authors: chu cy. JAMA Dermatol. 2024 Jan 1;160(1):37-44. doi: 10.1001/jamadermatol.2023.4450. JAMA Dermatol. 2024. PMID: 37966824
Pembrolizumab-induced linear psoriasis.
Huang PW, Chu CY. Huang PW, et al. Among authors: chu cy. Lung Cancer. 2020 Aug;146:378-379. doi: 10.1016/j.lungcan.2020.06.012. Epub 2020 Jun 17. Lung Cancer. 2020. PMID: 32586659 No abstract available.
Drug eruptions: Great imitators.
Chu CY. Chu CY. Clin Dermatol. 2020 Mar-Apr;38(2):193-207. doi: 10.1016/j.clindermatol.2019.10.005. Epub 2019 Oct 24. Clin Dermatol. 2020. PMID: 32513399 Review.
681 results